Sugi Predict

Sugi Predict / Targets / KDM1B

KDM1B

Lysine-specific histone demethylase 2 · Q8NB78 · KDM1B on Sugi Atlas →

12,460 patent compounds predicted against KDM1B, 6,861 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1506280 SCHEMBL1506280 0.56 6/20
SCHEMBL1506283 SCHEMBL1506283 0.56 6/20
SCHEMBL1479085 SCHEMBL1479085 0.50 6/20
SCHEMBL2636431 SCHEMBL2636431 0.47 6/20
SCHEMBL245340 SCHEMBL245340 0.69 5/20
SCHEMBL247873 SCHEMBL247873 0.69 5/20
SCHEMBL2612405 SCHEMBL2612405 0.69 5/20
SCHEMBL833057 SCHEMBL833057 0.52 5/20
SCHEMBL203096 SCHEMBL203096 0.52 5/20
SCHEMBL375373 SCHEMBL375373 0.50 5/20
SCHEMBL850836 SCHEMBL850836 0.50 5/20
SCHEMBL1664311 SCHEMBL1664311 0.50 5/20
SCHEMBL1664360 SCHEMBL1664360 0.48 5/20
SCHEMBL1666906 SCHEMBL1666906 0.48 5/20
SCHEMBL527343 SCHEMBL527343 0.45 5/20
SCHEMBL856202 SCHEMBL856202 0.44 5/20
SCHEMBL377065 SCHEMBL377065 0.41 5/20
SCHEMBL856379 SCHEMBL856379 0.39 5/20
SCHEMBL2560988 SCHEMBL2560988 0.84 4/20
SCHEMBL2561238 SCHEMBL2561238 0.76 4/20

Clinical trials — most relevant to KDM1B by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2 PHASE2ACTIVE_NOT_RECRUITING
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas PHASE1/PHASE2UNKNOWN
Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) PHASE1/PHASE2NOT_YET_RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia PHASE1RECRUITING
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
Lysine-specific Demethylase 1 and Salt-sensitivity in Humans nanACTIVE_NOT_RECRUITING
The Danish TURNER Cryopreservation Study nanRECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19 nanCOMPLETED
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer nanUNKNOWN
Expression of TET1 Gene in Acute Leukaemia nanUNKNOWN
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders nanCOMPLETED
The Molecular Pathogenesis Study of Cataract nanUNKNOWN
Mechanisms of Immune Deficiency nanUNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
X-chromosome Inactivation, Epigenetics and the Transcriptome nanCOMPLETED
Screening of IDH1 and IDH2 Gene Mutations in Adult Acute Myeloid Leukemia for Possible Targeted Therapy nanUNKNOWN
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia nanCOMPLETED
Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung Cancer nanUNKNOWN
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia nanUNKNOWN
OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a KDM1B binder may also engage these)

ProteinNameSimilarity
Q8CIG3 — 1.000 Q8CIG3 →
Q9CAE3 — 0.993 Q9CAE3 →
KDM5B Lysine-specific demethylase 5B 0.992 landscape →
KDM1A Lysine-specific histone demethylase 1A 0.991 landscape →
Q8BJM7 — 0.991 Q8BJM7 →
AS3MT Arsenite methyltransferase 0.991 landscape →
DHX29 ATP-dependent RNA helicase DHX29 0.990 landscape →
SMOX Spermine oxidase 0.990 landscape →
Q21988 — 0.990 Q21988 →
Q8H191 — 0.990 Q8H191 →
F4IDQ6 — 0.990 F4IDQ6 →
P18487 — 0.990 P18487 →
KDM5D Lysine-specific demethylase 5D 0.990 landscape →
Q19546 — 0.990 Q19546 →
Q7XR46 — 0.990 Q7XR46 →
Q5F3R2 — 0.989 Q5F3R2 →
Q6C710 — 0.989 Q6C710 →
Q9LID0 — 0.989 Q9LID0 →
Q28314 — 0.989 Q28314 →
Q6P158 — 0.989 Q6P158 →
Q6GM71 — 0.989 Q6GM71 →
O12990 — 0.989 O12990 →
Q61T02 — 0.989 Q61T02 →
Q6GPQ5 — 0.989 Q6GPQ5 →
Q90703 — 0.989 Q90703 →
Q8GWG2 — 0.989 Q8GWG2 →
Q9NPF8 — 0.989 Q9NPF8 →
Q6ZQ88 — 0.989 Q6ZQ88 →
A3KMI0 — 0.989 A3KMI0 →
KAT8 Histone acetyltransferase KAT8 0.989 landscape →